Want to see CVKD full AI Analyst Report?
Top Page
Cadrenal Therapeutics, Inc.
(NASDAQ:CVKD)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.50
▼(-3.23% Downside)
Action:Reiterated
Date:08/19/26
The score is held down primarily by weak financial performance (no revenue, sizeable losses, and continued cash burn) and bearish technicals (price below key moving averages and negative MACD). Corporate events provide some support via financing and a partnership-focused strategy, but leadership transition risk and the lack of earnings-based valuation support keep the overall score below average.
Positive Factors
Low Leverage
Minimal debt reduces interest burden and financial distress risk, giving Cadrenal greater flexibility to fund clinical development. However, this advantage supports resilience rather than eliminating the need for future equity or partnership financing.
Negative Factors
Pre-Revenue Business
Without product revenue, Cadrenal has no operating sales base to offset research, clinical and corporate costs. The company must create value through successful development, approvals and partnerships before it can demonstrate commercial operating leverage.
Read all positive and negative factors
Positive Factors
Negative Factors
Low Leverage
Minimal debt reduces interest burden and financial distress risk, giving Cadrenal greater flexibility to fund clinical development. However, this advantage supports resilience rather than eliminating the need for future equity or partnership financing.
Read all positive factors
Cadrenal Therapeutics, Inc. (CVKD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$5.58M
Dividend YieldN/A
Average Volume (3M)57.36K
Price to Earnings (P/E)―
Beta (1Y)1.27
Revenue GrowthN/A
EPS Growth44.80%
CountryUS
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.90
Shares Outstanding3,567,592
10 Day Avg. Volume57,981
30 Day Avg. Volume57,363
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)4.94
Price to Sales (P/S)0.00
P/FCF Ratio-1.07
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$29.00Price Target Upside1770.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-5.25
Revenue Forecast (FY)N/A
Cadrenal Therapeutics, Inc. Business Overview & Revenue Model
Company Description
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This ...
How the Company Makes Money
null...
Cadrenal Therapeutics, Inc. Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
58
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Mar 2026 | Dec 2024 | Dec 2023 | Dec 2022 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -956.00 | 0.00 | -1.88K | 0.00 | -1.27K |
| EBITDA | -11.56M | -13.23M | -10.65M | -8.34M | -6.61M |
| Net Income | -11.54M | -13.24M | -10.65M | -8.36M | -6.71M |
Balance Sheet | |||||
| Total Assets | 5.59M | 4.33M | 10.12M | 8.52M | 778.17K |
| Cash, Cash Equivalents and Short-Term Investments | 2.39M | 4.01M | 10.02M | 8.40M | 32.59K |
| Total Debt | 0.00 | 0.00 | 0.00 | 21.35K | 640.71K |
| Total Liabilities | 1.50M | 1.59M | 2.68M | 826.88K | 6.33M |
| Stockholders Equity | 4.09M | 2.74M | 7.44M | 7.69M | -5.55M |
Cash Flow | |||||
| Free Cash Flow | -10.16M | -12.60M | -7.36M | -3.53M | -1.32M |
| Operating Cash Flow | -10.16M | -12.60M | -7.36M | -3.53M | -1.31M |
| Investing Cash Flow | -412.00 | -5.10K | -6.54K | -3.25K | -2.49K |
| Financing Cash Flow | 6.98M | 6.60M | 8.98M | 11.90M | 1.35M |
Cadrenal Therapeutics, Inc. Technical Analysis
Negative
1.55
Price Trends
2.33
Negative
3.68
Negative
5.79
Negative
Market Momentum
-0.24
Negative
26.79
Positive
12.85
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CVKD, the sentiment is Negative. The current price of 1.55 is below the 20-day moving average (MA) of 1.79, below the 50-day MA of 2.33, and below the 200-day MA of 5.79, indicating a bearish trend. The MACD of -0.24 indicates Negative momentum. The RSI at 26.79 is Positive, neither overbought nor oversold. The STOCH value of 12.85 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CVKD.
Cadrenal Therapeutics, Inc. Risk Analysis
Cadrenal Therapeutics, Inc. disclosed 83 risk factors in its most recent earnings report. Cadrenal Therapeutics, Inc. reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Cadrenal Therapeutics, Inc. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $15.51M | -0.07 | -302.13% | ― | -97.99% | 99.28% | |
45 Neutral | $5.58M | -0.31 | -333.32% | ― | ― | 44.80% | |
43 Neutral | $5.48M | -0.35 | -160.28% | ― | -84.26% | 14.73% | |
42 Neutral | $14.53M | -0.93 | 763.44% | ― | ― | ― |
* Healthcare Sector Average
CVKD
Cadrenal Therapeutics, Inc.
1.54
-11.42
-88.12%
DARE
Daré Bioscience
0.74
-1.29
-63.61%
HIND
Vyome Holdings
2.21
-6.99
-76.03%
CLGN
Collplant Holdings
0.36
-2.26
-86.34%
LNAI
Lunai Bioworks
2.37
-16.67
-87.55%
TAOX
Tao Synergies
3.89
-1.93
-33.16%
Cadrenal Therapeutics, Inc. Corporate Events
Business Operations and StrategyProduct-Related Announcements
Cadrenal Therapeutics Launches Cardiac Acute Care Franchise Strategy
Positive
Jul 21, 2026
Cadrenal Therapeutics, Inc., a late-stage biopharmaceutical player in critical care cardiology and orphan cardiovascular diseases, has built a portfolio around CAD-1005 for heparin-induced thrombocytopenia, frunexian for cardiac surgery anticoagul...
Business Operations and StrategyExecutive/Board Changes
Cadrenal Therapeutics Announces Chief Medical Officer Transition
Negative
Jul 17, 2026
On July 14, 2026, Cadrenal Therapeutics entered into a confidential separation agreement with Chief Medical Officer James J. Ferguson III, following his July 7, 2026 resignation notice, effective July 31, 2026. Under the agreement, the company wil...
Business Operations and StrategyExecutive/Board Changes
Cadrenal Therapeutics Announces Chief Medical Officer Resignation
Negative
Jul 10, 2026
On July 7, 2026, Cadrenal Therapeutics disclosed that Chief Medical Officer James J. Ferguson III had submitted his resignation, with his departure effective July 31, 2026. The move prompted the company to begin a search for a new CMO while negoti...
Business Operations and StrategyPrivate Placements and Financing
Cadrenal Therapeutics Secures Private Placement to Extend Runway
Positive
Jul 1, 2026
On June 30, 2026, Cadrenal Therapeutics entered a definitive agreement with a single healthcare-focused institutional investor for a private placement of 960,000 shares of common stock or pre-funded warrants, together with series C-1 and C-2 warra...
Executive/Board Changes
Cadrenal Names Interim CFO, Realigns Board Structure
Neutral
Jun 29, 2026
On June 25, 2026, Cadrenal Therapeutics appointed veteran finance executive John P. Sharp as interim chief financial officer under a new statement of work with Lohman Associates, which will provide his services at a flat hourly rate capped at 24 ...
Business Operations and StrategyProduct-Related Announcements
Cadrenal Pursues Rare Pediatric Designation for Tecarfarin
Positive
Jun 18, 2026
On June 18, 2026, Cadrenal Therapeutics announced plans to seek Rare Pediatric Disease Designation from the U.S. Food and Drug Administration for tecarfarin as a chronic oral anticoagulant in pediatric patients with Kawasaki disease who develop co...
Executive/Board Changes
Cadrenal Therapeutics Announces CFO Transition and Interim Appointment
Neutral
Jun 3, 2026
On May 28, 2026, Cadrenal Therapeutics, Inc. and Chief Financial Officer Matthew K. Szot mutually agreed to his transition out of the CFO role, with CEO Quang X. Pham immediately assuming the positions of interim Chief Financial Officer and interi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.